Nephrotoxicity of anticancer drugs - An underestimated problem?

Acta Clinica Belgica

Volumn 66, Issue 5, 2011, Pages 337-345

  Lameire, N ^a   Kruse, V ^b   Rottey, S ^b  

^a Department of Medicine ^*  (Belgium)

^b GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

Cancer; Chemotherapy; Nephrotoxicity; Targeted agents

Indexed keywords

AMIFOSTINE; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CARBOPLATIN; CARBOXYPEPTIDASE G2; CETUXIMAB; CISPLATIN; CITUMIXAB; EPIDERMAL GROWTH FACTOR; ERLOTINIB; FOLINIC ACID; GEMCITABINE; IFOSFAMIDE; MAMMALIAN TARGET OF RAPAMYCIN; METHOTREXATE; MITOMYCIN C; OXALIPLATIN; PANITUMUMAB; SODIUM THIOSULFATE; UNCLASSIFIED DRUG; VASCULOTROPIN;

ACUTE KIDNEY FAILURE; AMINOACIDURIA; ANGIOGENESIS; ARTICLE; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CANCER PATIENT; CHRONIC KIDNEY DISEASE; CHRONIC KIDNEY FAILURE; CREATININE BLOOD LEVEL; DERMATITIS; DISTAL RENAL TUBULAR ACIDOSIS; DRUG MEGADOSE; EYTHROPOIETIN DEFICIENCY; FANCONI ANEMIA; GASTROINTESTINAL TOXICITY; GLOMERULUS FILTRATION RATE; GLUCOSURIA; HEPATITIS; HUMAN; HYPOCALCEMIA; HYPOKALEMIA; HYPOMAGNESEMIA; KIDNEY FAILURE; KIDNEY FUNCTION; MAGNESIUM BLOOD LEVEL; MOLECULARLY TARGETED THERAPY; MUCOSA INFLAMMATION; NEOPLASM; NEPHROTOXICITY; NEUROLOPATHY; NEUROPATHY; POTASSIUM BLOOD LEVEL; PROTEINURIA; RENAL CONCENTRATING DEFECT; RISK FACTOR; SALT WASTING; SIDE EFFECT; THROMBOTIC THROMBOCYTOPENIC PURPURA; TREATMENT OUTCOME; TREATMENT RESPONSE; URINALYSIS;

ACUTE KIDNEY INJURY; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CISPLATIN; DEOXYCYTIDINE; HUMANS; HYPERTENSION; IFOSFAMIDE; KIDNEY GLOMERULUS; METHOTREXATE; MITOMYCIN; RENAL INSUFFICIENCY, CHRONIC;

EID: 84555196859     PISSN: 00015512     EISSN: None     Source Type: Journal    
DOI: 10.2143/ACB.66.5.2062585     Document Type: Article

References (77)

1. Cummings BS, Schnellmann RG. Pathophysiology of nephrotoxic cell injury. In: Schrier RW, ed. Diseases of the kidney and urinary tract. Wolters, Kluwer, Lippincott, Williams and Wilkins, Philadelphia: 2007; 962-985.
2. Arany I, Kaushal GPI, Portilla D, Megyesi J, Price PM, Safirstein RL. Cellular mechanisms of nephrotoxicity. In: De Broe ME, Porter GA, Bennett WM, Debray G, eds. Clinical Nephrotoxins- renal injury from drugs and chemicals. Springer, 2008; 155-172.
3. Perazella MA, Moeckel GW. Nephrotoxicity from chemotherapeutic agents: Clinical manifestations, pathobiology, and prevention/therapy. Semin Nephrol 2010; 30: 570-581.
4. Skinner R. Nephrotoxicity-what do we know and what don't we know? J Pediatr Hematol Oncol 2011; 33: 128-134.
5. Lameire N, Van Biesen W, Vanholder R. Electrolyte disturbances and acute kidney injury in patients with cancer. Semin Nephrol 2010; 30: 534-547.
6. Satariano W. Comorbidities and cancer. In: Hunter C, Johnson K, Muss H, eds. Cancer in the elderly. Dekker M., New York: 2000; 477-500.
7. Yung KC, Piccirillo JF. The incidence and impact of comorbidity diagnosed after the onset of head and neck cancer. Arch Otolaryngol Head Neck Surg 2008; 134: 1045-1049.
8. Janssen-Heijnen ML, Maas HA, Houterman S, Lemmens VE, Rutten HJ, Coebergh JW. Comorbidity in older surgical cancer patients: Influence on patient care and outcome. Eur J Cancer 2007; 43: 2179-2193. (Pubitemid 47539116)
9. Safirstein RL. Renal diseases induced by antineoplastic agents. In: Schrier RW, ed. Diseases of the kidney and urinary tract. Wolters, Kluwer, Lippincott, Williams and Wilkins, Philadelphia: 2007; 1068-1081.
10. Launay-Vacher V, Spano JP, Janus N et al. Renal insufficiency and anticancer drugs in elderly cancer patients: A subgroup analysis of the IRMA study. Crit Rev Oncol Hematol 2009; 70: 124-133.
11. Lameire N. The kidney in oncology. Acta Clin Belg 2007; 62: 141-154. (Pubitemid 46999660)
12. Barraclough LH, Field C, Wieringa G, Swindell R, Livsey JE, Davidson SE. Estimation of renal function - what is appropriate in cancer patients? Clin Oncol (R Coll Radiol ) 2008; 20: 721-726.
13. Holweger K, Lipp HP, Dietz K, Hartmann JT, Bokemeyer C. Novel algorithm for more accurate calculation of renal function in adults with cancer. Ann Pharmacother 2008; 42: 1749-1757.
14. Kleber M, Cybulla M, Bauchmuller K, Ihorst G, Koch B, Engelhardt M. Monitoring of renal function in cancer patients: An ongoing challenge for clinical practice. Ann Oncol 2007; 18: 950-958. (Pubitemid 47054095)
15. Launay-Vacher V, Oudard S, Janus N et al. Prevalence of Renal Insufficiency in cancer patients and implications for anticancer drug management: The renal insufficiency and anticancer medications (IRMA) study. Cancer 2007; 110: 1376-1384. (Pubitemid 47435612)
16. Janus N, Launay-Vacher V, Byloos E et al. Cancer and renal insufficiency results of the BIRMA study. Br J Cancer 2010; 103: 1815-1821.
17. Isnard-Bagnis C, Launay-Vacher V, Karie S, Deray G. Anti -cancer drugs. In: De Broe ME, Porter GA, Bennett WM, Deray G, eds. Clinical Nephrotoxins-renal injury from drugs and chemicals. Springer, 2008; 512-535.
18. Sahni V, Choudhury D, Ahmed Z. Chemotherapy-associated renal dysfunction. Nat Rev Nephrol 2009; 5: 450-462.
19. Miller RP, Tadagavadi RK, Ramesh G, Reeves WB. Mechanism of cisplatin nephrotoxicity. Toxins 2010; 2: 2490-2518.
20. Pabla N, Dong Z. Cisplatin nephrotoxicity: Mechanisms and renoprotective strategies. Kidney Int 2008; 73: 994-1007. (Pubitemid 351543900)
21. Lajer H, Daugaard G. Cisplatin and hypomagnesemia. Cancer Treat Rev 1999; 25: 47-58. (Pubitemid 29178536)
22. Koch Nogueira PC, Hadj-Aissa A, Schell M, Dubourg L, Brunat-Mentigny M, Cochat P. Long-term nephrotoxicity of cisplatin, ifosfamide, and methotrexate in osteosarcoma. Pediatr Nephrol 1998; 12: 572-575. (Pubitemid 28408229)
23. Stohr W, Paulides M, Bielack S et al. Nephrotoxicity of cisplatin and carboplatin in sarcoma patients: A report from the late effects surveillance system. Pediatr Blood Cancer 2007; 48: 140-147. (Pubitemid 44958269)
24. Hamdi T, Latta S, Jallad B, Kheir F, Alhosaini MN, Patel A. Cisplatin-induced renal salt wasting syndrome. South Med J 2010; 103: 793-799.
25. Moran SM, Myers BD. Course of acute renal failure studied by a model of creatinine kinetics. Kidney Int 1985; 27: 928-937. (Pubitemid 15035559)
26. Star RA. Treatment of acute renal failure. Kidney Int 1998; 54: 1817-1831. (Pubitemid 28533609)
27. Bonventre JV, Vaidya VS, Schmouder R, Feig P, Dieterle F. Next-generation biomarkers for detecting kidney toxicity. Nat Biotechnol 2010; 28: 436-440.
28. Coca SG, Parikh CR. Urinary biomarkers for acute kidney injury: Perspectives on translation. Clin J Am Soc Nephrol 2008; 3: 481-490.
29. Gaspari F, Cravedi P, Mandala M et al. Predicting Cisplatin-induced acute kidney injury by urinary neutrophil gelatinase-associated lipocalin excretion: A pilot prospective case-control study. Nephron Clin Pract 2010; 115: C154-c160.
30. Lameire NH, Vanholder RC, Van Biesen WA. How to use biomarkers efficiently in acute kidney injury. Kidney Int 2011; 79: 1047-1050.
31. Launay-Vacher V, Rey JB, Isnard-Bagnis C, Deray G, Daouphars M. Prevention of cisplatin nephrotoxicity: State of the art and recommendations from the European Society of Clinical Pharmacy Special Interest Group on Cancer Care. Cancer Chemother Pharmacol 2008; 61: 903-909.
32. Skinner R, Pearson AD, English MW et al. Cisplatin dose rate as a risk factor for nephrotoxicity in children. Br J Cancer 1998; 77: 1677-1682. (Pubitemid 28230473)
33. Capizzi RL. Amifostine reduces the incidence of cumulative nephrotoxicity from cisplatin: Laboratory and clinical aspects. Semin Oncol 1999; 26: 72-81. (Pubitemid 29246633)
34. Hensley ML, Hagerty KL, Kewalramani T et al. American Society of Clinical Oncology 2008 clinical practice guideline update: Use of chemotherapy and radiation therapy protectants. J Clin Oncol 2009; 27: 127-145.
35. Brillet G, Deray G, Jacquiaud C et al. Long-term renal effect of cisplatin in man. Am J Nephrol 1994; 14: 81-84. (Pubitemid 24182574)
36. Skinner R, Parry A, Price L, Cole M, Craft AW, Pearson AD. Persistent nephrotoxicity during 10-year follow-up after cisplatin or carboplatin treatment in childhood: Relevance of age and dose as risk factors. Eur J Cancer 2009; 45: 3213-3219.
37. Martinez F, Deray G, Dubois M et al. Comparative nephrotoxicity of carboplatin and cisplatin in euvolemic and dehydrated rats. Anticancer Drugs 1993; 4: 85-90. (Pubitemid 23063738)
38. Cassidy J, Misset JL. Oxaliplatin-related side effects: Characteristics and management. Semin Oncol 2002; 29: 11-20. (Pubitemid 35191037)
39. Balis FM. Pharmacokinetic drug interactions of commonly used anticancer drugs. Clin Pharmacokinet 1986; 11: 223-235. (Pubitemid 16079741)
40. de Miguel D, Garcia-Suarez J, Martin Y, Gil-Fernandez JJ, Burgaleta C. Severe acute renal failure following high-dose methotrexate therapy in adults with haematological malignancies: A significant number result from unrecognized co-administration of several drugs. Nephrol Dial Transplant 2008; 23: 3762-3766.
41. Widemann BC, Adamson PC. Understanding and managing methotrexate nephrotoxicity. Oncologist 2006; 11: 694-703. (Pubitemid 43967624)
42. Janeway KA, Grier HE. Sequelae of osteosarcoma medical therapy: A review of rare acute toxicities and late effects. Lancet Oncol 2010; 11: 670-678.
43. Molina R, Fabian C, Cowley B, Jr. Use of charcoal hemoperfusion with sequential hemodialysis to reduce serum methotrexate levels in a patient with acute renal insufficiency. Am J Med 1987; 82: 350-352.
44. Relling MV, Stapleton FB, Ochs J et al. Removal of methotrexate, leucovorin, and their metabolites by combined hemodialysis and hemoperfusion. Cancer 1988; 62: 884-888.
45. Berns JS, Haghighat A, Staddon A et al. Severe, irreversible renal failure after ifosfamide treatment. A clinicopathologic report of two patients. Cancer 1995; 76: 497-500.
46. Skinner R, Pearson AD, Price L, Coulthard MG, Craft AW. Nephrotoxicity after ifosfamide. Arch Dis Child 1990; 65: 732-738. (Pubitemid 20220431)
47. Skinner R. Chronic ifosfamide nephrotoxicity in children. Med Pediatr Oncol 2003; 41: 190-197. (Pubitemid 36910127)
48. Zamlauski-Tucker MJ, Morris ME, Springate JE. Ifosfamide metabolite chloroacetaldehyde causes Fanconi syndrome in the perfused rat kidney. Toxicol Appl Pharmacol 1994; 129: 170-175. (Pubitemid 24352635)
49. Rossi R, Godde A, Kleinebrand A et al. Unilateral nephrectomy and cisplatin as risk factors of ifosfamide-induced nephrotoxicity: Analysis of 120 patients. J Clin Oncol 1994; 12: 159-165.
50. Goorin AM, Harris MB, Bernstein M et al. Phase II/III trial of etoposide and highdose ifosfamide in newly diagnosed metastatic osteosarcoma: A pediatric oncology group trial. J Clin Oncol 2002; 20: 426-433. (Pubitemid 34072525)
51. Finkel KW, Foringer JR. Renal disease in patients with cancer. Nat Clin Pract Nephrol 2007; 3: 669-678. (Pubitemid 350146950)
52. Heney D, Wheeldon J, Rushworth P, Chapman C, Lewis IJ, Bailey CC. Progressive renal toxicity due to ifosfamide. Arch Dis Child 1991; 66: 966-970.
53. Loebstein R, Atanackovic G, Bishai R et al. Risk factors for long-term outcome of ifosfamide-induced nephrotoxicity in children. J Clin Pharmacol 1999; 39: 454-461. (Pubitemid 29356465)
54. Ross IL, Marais S, Raubenheimer P, Abratt R, Isaacs S, Soule S. Overt hypoadrenalism is uncommon in patients with stage 3 and 4 bronchogenic carcinoma. S Afr Med J 2003; 93: 695-699. (Pubitemid 37362163)
55. Suarez A, McDowell H, Niaudet P, Comoy E, Flamant F. Long-term follow-up of ifosfamide renal toxicity in children treated for malignant mesenchymal tumors: An International Society of Pediatric Oncology report. J Clin Oncol 1991; 9: 2177-2182.
56. Humphreys BD, Sharman JP, Henderson JM et al. Gemcitabine-associated thrombotic microangiopathy. Cancer 2004; 100: 2664-2670. (Pubitemid 38715773)
57. Humphreys BD, Soiffer RJ, Magee CC. Renal failure associated with cancer and its treatment: An update. J Am Soc Nephrol 2005; 16: 151-161. (Pubitemid 43073167)
58. Robinson ES, Khankin EV, Karumanchi SA, Humphreys BD. Hypertension induced by vascular endothelial growth factor signaling pathway inhibition: Mechanisms and potential use as a biomarker. Semin Nephrol 2010; 30: 591-601.
59. Broxterman HJ, Georgopapadakou NH. Anticancer therapeutics: "Addictive" targets, multi-targeted drugs, new drug combinations. Drug Resist Updat 2005; 8: 183-197. (Pubitemid 41446962)
60. Eremina V, Quaggin SE. Biology of anti-angiogenic therapy-induced thrombotic microangiopathy. Semin Nephrol 2010; 30: 582-590.
61. Robinson ES, Matulonis UA, Ivy P et al. Rapid development of hypertension and proteinuria with cediranib, an oral vascular endothelial growth factor receptor inhibitor. Clin J Am Soc Nephrol 2010; 5: 477-483.
62. Humphreys BD, Atkins MB. Rapid development of hypertension by sorafenib: Toxicity or target? Clin Cancer Res 2009; 15: 5947-5949.
63. Snider KL, Maitland ML. Cardiovascular toxicities: Clues to optimal administration of vascular endothelial growth factor signaling pathway inhibitors. Target Oncol 2009; 4: 67-76.
64. Escudier B, Pluzanska A, Koralewski P et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: A randomised, double-blind phase III trial. Lancet 2007; 370: 2103-2111. (Pubitemid 350296300)
65. Yang JC, Haworth L, Sherry RM et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003; 349: 427-434. (Pubitemid 36910021)
66. Rixe O, Bukowski RM, Michaelson MD et al. Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: A phase II study. Lancet Oncol 2007; 8: 975-984. (Pubitemid 47629888)
67. Eremina V, Jefferson JA, Kowalewska J et al. VEGF inhibition and renal thrombotic microangiopathy. N Engl J Med 2008; 358: 1129-1136. (Pubitemid 351398487)
68. Levine RJ, Maynard SE, Qian C et al. Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med 2004; 350: 672-683. (Pubitemid 38364626)
69. Levine RJ, Lam C, Qian C et al. Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. N Engl J Med 2006; 355: 992-1005. (Pubitemid 44343543)
70. Patel TV, Morgan JA, Demetri GD et al. A preeclampsia-like syndrome characterized by reversible hypertension and proteinuria induced by the multitargeted kinase inhibitors sunitinib and sorafenib. J Natl Cancer Inst 2008; 100: 282-284. (Pubitemid 351480534)
71. Skotnicki JS, Leone CL, Smith AL et al. Design, synthesis and biological evaluation of C-42 hydroxyesters of rapamycin: The identification of CCI-779 (abstract). Clin cancer Res 2001; 7: 3749S-3750S.
72. Abraham RT, Gibbons JJ. The mammalian target of rapamycin signalling pathway: Twists and turns in the road to cancer therapy. Clin Cancer Res 2007; 13: 3109-3114. (Pubitemid 46944891)
73. Bellmunt J, Szczylik C, Feingold J, Strahs A and Berkenblit A. Temsirolimus safety profile and management of toxic effects in patients with advanced renal cell carcinoma and poor prognostic features. Ann Oncol 2008; 19: 1387-1392.
74. Letavernier E, Legendre C. mTOR inhibitirs-induced proteinuria: Mechanisms significance, and management. Transpl Rev 2008; 22: 125-130. (Pubitemid 351372914)
75. Miller AA, Murry DJ, Owzar K et al. Phase I and pharmacokinetic study of sorafenib in patients with hepatic or renal dysfunction: CALGB 60301. J Clin Oncol. 2009 Apr 10; 27(11): 1800-1805.
76. Masutani K, Fujisaki K, Maeda H et al. Tubulointerstitial nephritis and IgA nephropathy in a patient with advanced lung cancer and treated with longterm gefitinib. Clin Exp Nephrol; 2008 12(5): 398-402.
77. Medina PJ, Goodin S. Lapatinib: A dual inhibitor of human epidermal growth factor receptor tyrosinek kinases. Clin Ther 2008; 30 (8): 1426-1447.